[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019010143A - Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmune contra una infeccion respiratoria por virus. - Google Patents

Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmune contra una infeccion respiratoria por virus.

Info

Publication number
MX2019010143A
MX2019010143A MX2019010143A MX2019010143A MX2019010143A MX 2019010143 A MX2019010143 A MX 2019010143A MX 2019010143 A MX2019010143 A MX 2019010143A MX 2019010143 A MX2019010143 A MX 2019010143A MX 2019010143 A MX2019010143 A MX 2019010143A
Authority
MX
Mexico
Prior art keywords
bifidobacterium longum
immune response
virus infection
respiratory virus
modulate immune
Prior art date
Application number
MX2019010143A
Other languages
English (en)
Inventor
O'mahony Liam
Kiely Barry
GROEGER David
Original Assignee
Alimentary Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alimentary Health Ltd filed Critical Alimentary Health Ltd
Publication of MX2019010143A publication Critical patent/MX2019010143A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Una cepa aislada de Bifidobacterium Iongum NCIMB 42020 es útil para el tratamiento de infecciones virales, especialmente infecciones respiratorias virales tales como influenza, rinovirus y RSV. Bifidobacterium Iongum NCIMB 42020 también es útil para eliminar infecciones bacterianas secundarias.
MX2019010143A 2017-02-28 2018-02-28 Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmune contra una infeccion respiratoria por virus. MX2019010143A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17158567 2017-02-28
EP17158564 2017-02-28
PCT/EP2018/054914 WO2018158306A1 (en) 2017-02-28 2018-02-28 Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection

Publications (1)

Publication Number Publication Date
MX2019010143A true MX2019010143A (es) 2019-10-02

Family

ID=61521511

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010143A MX2019010143A (es) 2017-02-28 2018-02-28 Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmune contra una infeccion respiratoria por virus.

Country Status (13)

Country Link
US (1) US11529381B2 (es)
EP (1) EP3532603B1 (es)
JP (1) JP7055814B2 (es)
KR (1) KR20190123267A (es)
CN (1) CN110352237B (es)
AU (1) AU2018227020B2 (es)
BR (1) BR112019017940A2 (es)
CA (1) CA3054099A1 (es)
DK (1) DK3532603T3 (es)
ES (1) ES2834950T3 (es)
MX (1) MX2019010143A (es)
RU (1) RU2768030C2 (es)
WO (1) WO2018158306A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2500618C2 (ru) * 2008-05-27 2013-12-10 Спонт Прайват С.А.Р.Л. Галогенидсодержащий кремний, способ его получения и его применение
EP3634434A4 (en) * 2017-05-12 2021-06-09 The Regents of The University of California TREATMENT AND DETECTION OF DYSBIOSIS
JP2019167327A (ja) * 2018-03-26 2019-10-03 森永乳業株式会社 ビフィドバクテリウム属細菌を有効成分とする、ｉｉｉ型インターフェロン産生促進用組成物
AR119031A1 (es) * 2019-05-28 2021-11-17 Aybar Ecotechnologies Corp Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de utilización de la misma
WO2021180973A1 (en) * 2020-03-13 2021-09-16 Precisionbiotics Group Limited Bifidobacterium longum
CN111529703B (zh) * 2020-06-17 2023-09-15 湖南循天然营养有限公司 一种组合物及其制备方法与在制备免疫佐剂中的应用
US20240124617A1 (en) * 2021-02-11 2024-04-18 Danstar Ferment Ag Compositions comprising exopolysaccharides and uses thereof
CN118475359A (zh) * 2021-12-22 2024-08-09 株式会社明治 用于预防继发感染症或用于降低继发感染症发生风险的组合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1598457A (en) 1977-03-22 1981-09-23 Glaxo Lab Ltd Process for the preparation of a fraction containing peptidoglycan material from streptomyces griseus
DE3024318A1 (de) 1980-06-27 1982-01-28 Chemisches Laboratorium Dr. Karl Richter GmbH, 1000 Berlin Kosmetische mittel
RU2151606C1 (ru) * 1998-07-09 2000-06-27 Российский государственный медицинский университет Штамм бактерий bifidobacterium longum z4 для приготовления бактерийных препаратов, нормализующих микрофлору при нарушениях микробиоценоза влагалища
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
RU2216588C1 (ru) * 2002-05-17 2003-11-20 Государственное учреждение Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н.Габричевского Штамм bifidobacterium longum я2, используемый для получения кисломолочных, ферментированных и неферментированных пищевых продуктов, заквасок, гигиенических и косметических средств, биологически активных добавок и бактерийных препаратов
CN1183960C (zh) 2003-02-27 2005-01-12 四川大学 双歧杆菌细胞壁蛋白在制药中的应用
JP2007169200A (ja) 2005-12-21 2007-07-05 Morinaga Milk Ind Co Ltd インフルエンザ感染予防のための医薬及び飲食品
RU2314341C1 (ru) * 2006-07-13 2008-01-10 Федеральное Государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Штамм bifidobacterium longum гв-15, используемый для получения кисломолочных, ферментированных и неферментированных пищевых продуктов, заквасок, гигиенических и косметических средств, биологически активных добавок и бактерийных препаратов
US20080118473A1 (en) 2006-11-01 2008-05-22 The Procter & Gamble Company Methods of treating a respiratory condition comprising probiotic treatment
KR20100016012A (ko) * 2007-03-28 2010-02-12 앨러멘터리 헬스 리미티드 프로바이오틱 비피도박테리움 스트레인
BRPI0809448A2 (pt) 2007-03-28 2014-09-09 Alimentary Health Ltd Cepas de bifidobacterium probióticas
ZA200907742B (en) * 2007-05-04 2010-07-28 Alimentary Health Ltd An exopolysaccharide
AU2009212295A1 (en) * 2008-02-06 2009-08-13 The Procter & Gamble Company Compositions methods and kits for enhancing immune response to a respiratory condition
CA2716923A1 (en) * 2008-03-17 2009-09-24 The Procter & Gamble Company User-customizable dosing system
FR2937547B1 (fr) 2008-10-28 2012-11-09 Oreal Utilisation d'un lysat de microorganisme pour le traitement des peaux grasses
TR201807143T4 (tr) * 2009-08-25 2018-06-21 Nestec Sa Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar.
FI20096058A0 (fi) * 2009-10-13 2009-10-13 Valio Oy Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
CN107574131A (zh) * 2009-11-11 2018-01-12 营养健康有限公司 益生菌双歧杆菌菌株
EP2498790A1 (en) * 2009-11-11 2012-09-19 Alimentary Health Limited A bifidobacterium strain
EP2611484A4 (en) 2010-09-02 2016-03-09 Sipnose Ltd DEVICE FOR NASAL ADMINISTRATION
EP2455092A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
CN102321187B (zh) 2011-08-15 2013-04-17 内蒙古双奇药业股份有限公司 一种从长双歧杆菌nq-1501中提取完整肽聚糖的方法
US20130165470A1 (en) * 2011-12-21 2013-06-27 The Procter & Gamble Company Methods for Detecting and Treating Rhinovirus Infection
EP3033351A4 (en) 2013-08-12 2017-03-22 Mansel Griffiths Antiviral methods and compositions comprising probiotic bacterial molecules
WO2015140299A1 (en) * 2014-03-20 2015-09-24 Universiteit Antwerpen Oronasopharyngeal probiotics
PT3049430T (pt) 2014-07-16 2019-03-27 Depofarma S P A Fração parietal de propionibacterium granulosum que tem ação imunomoduladora
AU2016212100B2 (en) * 2015-01-27 2019-02-21 International N&H Denmark Aps Immunomodulatory composition comprising bifidobacteria
EP3268017A1 (en) 2015-03-09 2018-01-17 Bioimmunizer SAGL Anti-age composition comprising a combination of antioxidant agents in association with bifidobacteria and cell walls isolated from probiotics
WO2017032897A1 (en) * 2015-08-27 2017-03-02 Alimentary Health Limited Use of bifidobacterium longum and an exopolysaccharide produced thereby
JP6637725B2 (ja) 2015-10-28 2020-01-29 ビオフェルミン製薬株式会社 ウイルス感染症の予防及び／又は治療剤
IT201600091033A1 (it) 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
US11590179B2 (en) 2017-02-28 2023-02-28 Precisionbiotics Group Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
JPWO2018168449A1 (ja) 2017-03-17 2020-01-16 国立大学法人東北大学 ペプチドグリカン認識タンパク質産生促進用組成物

Also Published As

Publication number Publication date
EP3532603B1 (en) 2020-09-09
RU2019128539A3 (es) 2021-07-01
KR20190123267A (ko) 2019-10-31
AU2018227020A1 (en) 2019-08-29
CN110352237B (zh) 2023-01-10
EP3532603A1 (en) 2019-09-04
US20200000859A1 (en) 2020-01-02
CA3054099A1 (en) 2018-09-07
DK3532603T3 (da) 2020-12-07
RU2019128539A (ru) 2021-03-30
RU2768030C2 (ru) 2022-03-23
JP2020508672A (ja) 2020-03-26
WO2018158306A1 (en) 2018-09-07
ES2834950T3 (es) 2021-06-21
CN110352237A (zh) 2019-10-18
WO2018158306A8 (en) 2019-04-25
BR112019017940A2 (pt) 2020-05-19
AU2018227020B2 (en) 2023-08-17
US11529381B2 (en) 2022-12-20
JP7055814B2 (ja) 2022-04-18

Similar Documents

Publication Publication Date Title
MX2019010143A (es) Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmune contra una infeccion respiratoria por virus.
MX2018008413A (es) Virus oncolitico modificado.
EA201990566A1 (ru) Композиции, содержащие бактериальные штаммы
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
EP4414385A3 (en) Polyomavirus neutralizing antibodies
EP3474861A4 (en) COMPOUNDS COMPRISING HMOS FOR THE PREVENTION AND / OR TREATMENT OF VIRAL AND / OR BACTERIAL INFECTIONS.
WO2019106578A3 (en) Polyomavirus neutralizing antibodies
PH12018550110A1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
WO2018231992A3 (en) METHODS OF USING LACTOBACILLUS PLANTARUM STRAINS TO PROTECT ANIMALS AGAINST PATHOGENIC BACTERIAL INFECTION
WO2017147130A3 (en) Direct fed microbial for prevention of shrimp disease
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
WO2016205641A3 (en) Respiratory syncytial virus having cleavage-resistant g protein and related materials and methods
MX2021012984A (es) Anticuerpos y metodos para el tratamiento de la infeccion por influenza a.
WO2017123610A3 (en) Bacteria engineered to detoxify deleterious molecules
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
WO2023004415A3 (en) Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments
EA202190876A1 (ru) Композиции, содержащие бактериальные штаммы
PH12019550183A1 (en) Treatment of infant colic
WO2018237010A3 (en) VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
MX2017007969A (es) Bacterias de acido lactico y su uso para el tratamiento de mastitis.
WO2017053525A3 (en) Influenza vaccine and therapy
MX2022003871A (es) Composiciones inmunogénicas.
AU2018257122A1 (en) Pharmaceutical composition comprising attenuated streptococcus pneumoniae strains and use thereof
WO2018236086A3 (ko) 신규한 에로모나스 하이드로필라 박테리오파지 Aer-HYP-2 및 이의 에로모나스 하이드로필라 균 증식 억제 용도